Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01701973 · ClinicalTrials.gov registry record · Phase 4
Effect of DPP4 Inhibition on Growth Hormone Secretion
A Phase 4 study, sponsored by Vanderbilt University.
- Completed
- Registry status
- Phase 4
- Development phase
- 44
- Enrollment target
NCT01701973 is a Phase 4 study that has completed, run by Vanderbilt University. The registered enrollment target is 44 participants.
The verdict
NCT01701973, a Phase 4 study, has completed, sponsored by Vanderbilt University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 44 participants
- Enrollment target
Study Summary
This study tests the following hypotheses: Aim 1: Test the hypothesis that acute dipeptidyl peptidase 4 (DPP4) inhibition with the currently available anti-diabetic drug, sitagliptin, will increase stimulated growth hormone (GH) secretion in healthy lean adults by decreasing the degradation of growth hormone releasing hormone (GHRH). Aim 2: Test the hypothesis that decreased degradation of GHRH during acute DPP4 inhibition will result in an increase in endothelium-dependent vasodilation mediated by GH and independent from GLP1 (glucagon like peptide-1) in healthy lean adults. This study promises to provide novel data regarding how this increasingly used class of anti-diabetic drugs affects the pituitary GH axis and could affect blood vessel relaxation. Growth hormone levels are low in the setting of obesity and pre-diabetes. A further study may evaluate the effect of chronic DPP4 inhibitor therapy in a population of patients with obesity and pre-diabetes.
Interventions
- DRUG Placebo
- DRUG Sitagliptin
- DRUG L-NMMA
- DRUG Pegvisomant
- DRUG Exendin 9-39
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2013-01 |
| Est. Completion | 2017-05 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01701973
The ClinicalTrials.gov registry entry for NCT01701973 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt University, which has 430 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT01701973 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01701973 about?
NCT01701973 is a clinical study titled "Effect of DPP4 Inhibition on Growth Hormone Secretion". This study tests the following hypotheses: Aim 1: Test the hypothesis that acute dipeptidyl peptidase 4 (DPP4) inhibition with the currently available anti-diabetic drug, sitagliptin, will increase stimulated growth hormone (GH) secretion in healthy lean adults by decreasing the degradation of grow...
What is the current status of trial NCT01701973?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 44 participants. The study started on 2013-01. Estimated completion is 2017-05.
What interventions are being tested in trial NCT01701973?
The interventions under investigation include: Placebo (DRUG), Sitagliptin (DRUG), L-NMMA (DRUG), Pegvisomant (DRUG), Exendin 9-39 (DRUG).
Who is sponsoring clinical trial NCT01701973?
This trial is sponsored by Vanderbilt University, which has 430 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.